Pulmonary microcirculation in interstitial lung disease

Proceedings of the American Thoracic Society

Volumn 8, Issue 6, 2011, Pages 516-521

  Farkas, Laszlo ^a,b,c   Kolb, Martin ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Angiogenesis; Fibrosis; ILD; Pulmonary hypertension; Vasculature

Indexed keywords

GROWTH FACTOR; PIGMENT EPITHELIUM DERIVED FACTOR; VASCULOTROPIN;

ANGIOGENESIS; CONFERENCE PAPER; DISEASE ASSOCIATION; ENDOTHELIUM CELL; HUMAN; IMMUNE RESPONSE; INTERSTITIAL LUNG DISEASE; LUNG BLOOD VESSEL; LUNG CIRCULATION; LUNG FIBROSIS; LUNG SARCOIDOSIS; MICROCIRCULATION; PATHOGENESIS; PULMONARY HYPERTENSION; SCLERODERMA;

HUMANS; LUNG DISEASES, INTERSTITIAL; MICROCIRCULATION; MODELS, BIOLOGICAL; PULMONARY CIRCULATION; PULMONARY FIBROSIS; SCLERODERMA, LOCALIZED;

EID: 80655125168     PISSN: 15463222     EISSN: 19435665     Source Type: Journal    
DOI: 10.1513/pats.201101-007MW     Document Type: Conference Paper

References (72)

1. Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK, Hirani N, Hubbard R, Lake F, Millar AB, et al. Interstitial lung disease guideline: The British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008;63:v1-v58.
2. American Thoracic Society/European Respiratory Society. International multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002;165:277-304.
3. American Thoracic Society and the European Respiratory Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000;161:646-664.
4. Behr J, Ryu JH. Pulmonary hypertension in interstitial lung disease. Eur Respir J 2008;31:1357-1367.
5. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006;129:746-752.
6. Nathan SD, Noble PW, Tuder RM. Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots. Am J Respir Crit Care Med 2007;175:875-880. (Pubitemid 46684695)
7. Shorr AF, Davies DB, Nathan SD. Outcomes for patients with sarcoidosis awaiting lung transplantation. Chest 2002;122:233-238. (Pubitemid 34754168)
8. Nadrous HF, Pellikka PA, Krowka MJ, Swanson KL, Chaowalit N, Decker PA, Ryu JH. The impact of pulmonary hypertension on survival in patients with idiopathic pulmonary fibrosis. Chest 2005;128 (Suppl)616S-617S. (Pubitemid 43054163)
9. Nathan SD, Shlobin OA, Ahmad S, Koch J, Barnett SD, Ad N, Burton N, Leslie K. Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respiration 2008;76: 288-294.
10. Ryu JH, Krowka MJ, Pellikka PA, Swanson KL, McGoon MD. Pulmonary hypertension in patients with interstitial lung diseases. Mayo Clin Proc 2007;82:342-350. (Pubitemid 46348935)
11. Strange C, Highland KB. Pulmonary hypertension in interstitial lung disease. Curr Opin Pulm Med 2005;11:452-455. (Pubitemid 41291091)
12. Farkas L, Farkas D, Ask K, Moller A, Gauldie J, Margetts P, Inman M, Kolb M. VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats. J Clin Invest 2009;119:1298-1311.
13. Hislop AA. Airway and blood vessel interaction during lung development. J Anat 2002;201:325-334. (Pubitemid 35244052)
14. Hall SM, Hislop AA, Haworth SG. Origin, differentiation, and maturation of human pulmonary veins. Am J Respir Cell Mol Biol 2002;26: 333-340. (Pubitemid 34170059)
15. Hall SM, Hislop AA, Pierce CM, Haworth SG. Prenatal origins of human intrapulmonary arteries: formation and smooth muscle maturation. Am J Respir Cell Mol Biol 2000;23:194-203. (Pubitemid 30656429)
16. Hislop A, Reid L. Fetal and childhood development of the intrapulmonary veins in man: branching pattern and structure. Thorax 1973;28:313-319.
17. Hislop A, Reid L. Intra-pulmonary arterial development during fetal life-branching pattern and structure. J Anat 1972;113:35-48.
18. deMello DE, Sawyer D, Galvin N, Reid LM. Early fetal development of lung vasculature. Am J Respir Cell Mol Biol 1997;16:568-581. (Pubitemid 127498289)
19. Bhandari V, Choo-Wing R, Chapoval SP, Lee CG, Tang C, Kim YK, Ma B, Baluk P, Lin MI,McDonald DM, et al. Essential role of nitric oxide in VEGF-induced, asthma-like angiogenic, inflammatory, mucus, and physiologic responses in the lung. Proc Natl Acad Sci USA 2006;103: 11021-11026. (Pubitemid 44148411)
20. Mitzner W, Wagner EM. Vascular remodeling in the circulations of the lung. J Appl Physiol 2004;97:1999-2004. (Pubitemid 39426022)
21. Shi W, Xu J, Warburton D. Development, repair and fibrosis: what is common and why it matters. Respirology 2009;14:656-665.
22. Tuder RM, Yun JH. Vascular endothelial growth factor of the lung: friend or foe. Curr Opin Pharmacol 2008;8:255-260.
23. Shifren JL, Doldi N, Ferrara N, Mesiano S, Jaffe RB. In the human fetus, vascular endothelial growth factor is expressed in epithelial cells and myocytes, but not vascular endothelium: implications for mode of action. J Clin Endocrinol Metab 1994;79:316-322. (Pubitemid 24221202)
24. Acarregui MJ, Penisten ST, Goss KL, Ramirez K, Snyder JM. Vascular endothelial growth factor gene expression in human fetal lung in vitro. Am J Respir Cell Mol Biol 1999;20:14-23. (Pubitemid 129504838)
25. Healy AM, Morgenthau L, Zhu X, Farber HW, Cardoso WV. VEGF is deposited in the subepithelial matrix at the leading edge of branching airways and stimulates neovascularization in the murine embryonic lung. Dev Dyn 2000;219:341-352.
26. Ng YS, Rohan R, Sunday ME, Demello DE, D'Amore PA. Differential expression of VEGF isoforms in mouse during development and in the adult. Dev Dyn 2001;220:112-121. (Pubitemid 32107812)
27. Farkas L, Gauldie J, Voelkel NF, Kolb M. Pulmonary hypertension and idiopathic pulmonary fibrosis: a tale of angiogenesis, apoptosis and growth factors. Am J Respir Cell Mol Biol 2011;45:1-15.
28. Sato TN, Tozawa Y, Deutsch U, Wolburg-Buchholz K, Fujiwara Y, Gendron-Maguire M, Gridley T, Wolburg H, Risau W, Qin Y. Distinct roles of the receptor tyrosine kinases tie-1 and tie-2 in blood vessel formation. Nature 1995;376:70-74.
29. Zeng X, Gray M, Stahlman MT, Whitsett JA. TGF-beta1 perturbs vascular development and inhibits epithelial differentiation in fetal lung in vivo. Dev Dyn 2001;221:289-301. (Pubitemid 32601827)
30. Kottmann RM, Hogan CM, Phipps RP, Sime PJ. Determinants of initiation and progression of idiopathic pulmonary fibrosis. Respirology 2009;14:917-933.
31. Lu Q, Patel B, Harrington EO, Rounds S. Transforming growth factorb1 causes pulmonary microvascular endothelial cell apoptosis via alk5. Am J Physiol Lung Cell Mol Physiol 2009;296:L825-L838.
32. Turner-Warwick M. Precapillary systemic-pulmonary anastomoses. Thorax 1963;18:225-237.
33. Keane MP, Arenberg DA, Lynch JP III, Whyte RI, Iannettoni MD, Burdick MD, Wilke CA, Morris SB, Glass MC, DiGiovine B, et al. The cxc chemokines, il-8 and ip-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol 1997;159:1437-1443. (Pubitemid 127484123)
34. Keane MP, Belperio JA, Burdick MD, Lynch JP, Fishbein MC, Strieter RM. Ena-78 is an important angiogenic factor in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001;164:2239-2242. (Pubitemid 34032941)
35. Burdick MD, Murray LA, Keane MP, Xue YY, Zisman DA, Belperio JA, Strieter RM. Cxcl11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling. Am J Respir Crit Care Med 2005;171:261-268.
36. Keane MP, Belperio JA, Moore TA, Moore BB, Arenberg DA, Smith RE, Burdick MD, Kunkel SL, Strieter RM. Neutralization of the cxc chemokine, macrophage inflammatory protein-2, attenuates bleomycin-induced pulmonary fibrosis. J Immunol 1999;162:5511-5518. (Pubitemid 29307163)
37. Ebina M, Shimizukawa M, Shibata N, Kimura Y, Suzuki T, Endo M, Sasano H, Kondo T, Nukiwa T. Heterogeneous increase in cd34- positive alveolar capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2004;169:1203-1208. (Pubitemid 38680397)
38. Cosgrove GP, Brown KK, Schiemann WP, Serls AE, Parr JE, Geraci MW, Schwarz MI, Cool CD, Worthen GS. Pigment epitheliumderived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. Am J Respir Crit Care Med 2004;170:242-251. (Pubitemid 38971408)
39. Simler NR, Brenchley PE, Horrocks AW, Greaves SM, Hasleton PS, Egan JJ. Angiogenic cytokines in patients with idiopathic interstitial pneumonia. Thorax 2004;59:581-585. (Pubitemid 38901516)
40. Tachihara A, Jin E, Matsuoka T, Ghazizadeh M, Yoshino S, Takemura T, D Travis W, Kawanami O. Critical roles of capillary endothelial cells for alveolar remodeling in nonspecific and usual interstitial pneumonias. J Nippon Med Sch 2006;73:203-213. (Pubitemid 44274095)
41. Renzoni EA, Walsh DA, Salmon M, Wells AU, Sestini P, Nicholson AG, Veeraraghavan S, Bishop AE, Romanska HM, Pantelidis P, et al. Interstitial vascularity in fibrosing alveolitis. Am J Respir Crit Care Med 2003;167:438-443. (Pubitemid 36216429)
42. Sakao S, Taraseviciene-Stewart L, Wood K, Cool CD, Voelkel NF. Apoptosis of pulmonary microvascular endothelial cells stimulates vascular smooth muscle cell growth. Am J Physiol Lung Cell Mol Physiol 2006;291:L362-L368. (Pubitemid 44343711)
43. Bournia V, Vlachoyiannopoulos P, Selmi C, Moutsopoulos H, Gershwin M. Recent advances in the treatment of systemic sclerosis. Clin Rev Allergy Immunol 2009;36:176-200.
44. Antoniou KM, Wells AU. Scleroderma lung disease: evolving understanding in light of newer studies. Curr Opin Rheumatol 2008;20:686-691.
45. Bouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P, Haslam PL, Vassilakis DA, Black CM, du Bois RM. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002;165:1581-1586. (Pubitemid 34693935)
46. du Bois RM. Mechanisms of scleroderma-induced lung disease. Proc Am Thorac Soc 2007;4:434-438.
47. NicollsMR, Taraseviciene-Stewart L, Rai PR, Badesch DB, Voelkel NF. Autoimmunity and pulmonary hypertension: a perspective.Eur Respir J 2005;26:1110-1118. (Pubitemid 41829945)
48. Okano Y, Medsger TA Jr. Autoantibody to th ribonucleoprotein (nucleolar 7-2 rna protein particle) in patients with systemic sclerosis. Arthritis Rheum 1990;33:1822-1828.
49. Negi VS, Tripathy NK, Misra R, Nityanand S. Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. J Rheumatol 1998;25:462-466.
50. Luzina IG, Atamas SP, Wise R, Wigley FM, Xiao HQ, White B. Gene expression in bronchoalveolar lavage cells from scleroderma patients. Am J Respir Cell Mol Biol 2002;26:549-557. (Pubitemid 34315862)
51. Luzina IG, Atamas SP, Wise R, Wigley FM, Choi J, Xiao HQ, White B. Occurrence of an activated, profibrotic pattern of gene expression in lung cd81 t cells from scleroderma patients. Arthritis Rheum 2003;48: 2262-2274. (Pubitemid 36959208)
52. Scala E, Pallotta S, Frezzolini A, Abeni D, Barbieri C, Sampogna F, De Pita O, Puddu P, Paganelli R, Russo G. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol 2004;138:540-546. (Pubitemid 39573637)
53. Meloni F, Caporali R, Marone Bianco A, Paschetto E, Morosini M, Fietta AM, Bobbio-Pallavicini F, Pozzi E, Montecucco C. Cytokine profile of bronchoalveolar lavage in systemic sclerosis with interstitial lung disease: comparison with usual interstitial pneumonia. Ann Rheum Dis 2004;63:892-894. (Pubitemid 38850472)
54. Le Pavec J, Humbert M, Mouthon L, Hassoun PM. Systemic sclerosisassociated pulmonary arterial hypertension. Am J Respir Crit Care Med 2010;181:1285-1293.
55. Hassoun PM, Mouthon L, Barbera JA, Eddahibi S, Flores SC, Grimminger F, Jones PL, Maitland ML, Michelakis ED, Morrell NW, et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 2009;54(Suppl)S10-S19.
56. Guiducci S, Distler O, Distler JHW, Matucci-Cerinic M. Mechanisms of vascular damage in ssc-implications for vascular treatment strategies. Rheumatology 2008;47:v18-v20.
57. Laplante P, Raymond MA, Gagnon G, Vigneault N, Sasseville AM, Langelier Y, Bernard M, Raymond Y, Hebert MJ. Novel fibrogenic pathways are activated in response to endothelial apoptosis: implications in the pathophysiology of systemic sclerosis. J Immunol 2005; 174:5740-5749. (Pubitemid 40593217)
58. Gerke AK, Hunninghake G. The immunology of sarcoidosis. Clin Chest Med 2008;29:379-390, vii. (Pubitemid 351778215)
59. Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med 2011;183:573-581.
60. Takemura T, Hiraga Y, Oomichi M, Oritsu M, Akiyama O, Matsui Y, Eishi Y, Mikami R. Ultrastructural features of alveolitis in sarcoidosis. Am J Respir Crit Care Med 1995;152:360-366.
61. Diaz-Guzman E, Farver C, Parambil J, Culver DA. Pulmonary hypertension caused by sarcoidosis. Clin Chest Med 2008;29:549-563. (x.). (Pubitemid 351778207)
62. Rosen Y, Moon S, Huang CT, Gourin A, Lyons HA. Granulomatous pulmonary angiitis in sarcoidosis. Arch Pathol Lab Med 1977;101:170-174. (Pubitemid 8187786)
63. Takemura T, Matsui Y, Oritsu M, Akiyama O, Hiraga Y, Omichi M, Hirasawa M, Saiki S, Tamura S, Mochizuki I, et al. Pulmonary vascular involvement in sarcoidosis: granulomatous angiitis and microangiopathy in transbronchial lung biopsies. Virchows Arch A Pathol Anat Histopathol 1991;418:361-368.
64. Reichenberger F, Schauer J, Kellner K, Sack U, Stiehl P, Winkler J. Different expression of endothelin in the bronchoalveolar lavage in patients with pulmonary diseases. Lung 2001;179:163-174. (Pubitemid 34033112)
65. Koyama S, Sato E, Haniuda M, Numanami H, Nagai S, Izumi T. Decreased level of vascular endothelial growth factor in bronchoalveolar lavage fluid of normal smokers and patients with pulmonary fibrosis. Am J Respir Crit Care Med 2002;166:382-385. (Pubitemid 34864431)
66. Hofmann S, Franke A, Fischer A, Jacobs G, Nothnagel M, Gaede KI, Schurmann M, Muller-Quernheim J, Krawczak M, Rosenstiel P, et al. Genome-wide association study identifies anxa11 as a new susceptibility locus for sarcoidosis. Nat Genet 2008;40:1103-1106.
67. Wasfi YS, Silveira LJ, Jonth A, Hokanson JE, Fingerlin T, Sato H, Parsons CE, Lympany P, Welsh K, du Bois RM, et al. Fas promoter polymorphisms: genetic predisposition to sarcoidosis in African- Americans. Tissue Antigens 2008;72:39-48. (Pubitemid 351841646)
68. Hashimoto N, Phan SH, Imaizumi K, Matsuo M, Nakashima H, Kawabe T, Shimokata K, Hasegawa Y. Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2010;43:161-172.
69. Bogaard HJ, Abe K, Vonk Noordegraaf A, Voelkel NF. The right ventricle under pressure. Chest 2009;135:794-804.
70. Richter AG, McKeown S, Rathinam S, Harper L, Rajesh P, McAuley DF, Heljasvaara R, Thickett DR. Soluble endostatin is a novel inhibitor of epithelial repair in idiopathic pulmonary fibrosis. Thorax 2009;64:156-161.
71. Strieter RM, Keeley EC, Hughes MA, Burdick MD, Mehrad B. The role of circulating mesenchymal progenitor cells (fibrocytes) in the pathogenesis of pulmonary fibrosis. J Leukoc Biol 2009;86:1111-1118.
72. Zhao YD, Courtman DW, Deng Y, Kugathasan L, Zhang Q, Stewart DJ. Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and enos gene therapy in established disease. Circ Res 2005;96:442-450. (Pubitemid 40354538)